



Neuren signs Agreement for US Army Participation in Phase 3 trial

24 November 2005: Neuren Pharmaceuticals (ASX: NEU) is pleased to announce the execution of a Memorandum of Understanding (MOU) with the Henry M. Jackson Foundation for the Advancement of Military Medicine (Jackson Foundation) for inclusion of US Army hospital sites in Neuren's forthcoming Phase 3 trial.

The Phase 3 trial is scheduled to start next year and will assess the effectiveness of the compound, Glypromate[®], in preventing neurocognitive decline following coronary artery bypass grafting surgery (CABG). A decline in cognitive function is a widely-recognised and clinically significant complication of CABG surgery. Following a meeting with the FDA in April 2005, Neuren has advanced its clinical development program for Glypromate[®] from a Phase 2a study directly into a Phase 3 pivotal study, representing significant savings in time and money in bringing Glypromate[®] to market.

Under the MOU, the Jackson Foundation will coordinate and review the clinical trial plans, assist in the negotiation of definitive agreements for the participation of US Army hospitals in the trial and support preparations for and the implementation of the Phase 3 trial.

US Army hospitals provide medical care to retired military members and their dependents as well as active duty personnel. Highly qualified scientists and physicians at the hospitals contribute to clinical and basic research programs. Army hospitals are recognised as world leading biomedical institutions across a wide range of scientific and therapeutic areas.

Mr David Clarke, CEO of Neuren commented: "Because of the quality and organisation of military medicine and the facilitating role that the Jackson Foundation provides, US military hospitals represent an excellent resource for high quality, cost-effective participation in the Glypromate[®] Phase 3 trial."

Neuren already has a very productive Cooperative Research and Development Agreement with the US Army Walter Reed Army Institute of Research to develop its second lead compound, NNZ-2566, as an effective treatment for traumatic brain injury (TBI).

Over 400,000 patients undergo CABG surgery each year in the US and some loss of brain function has been reported in up to 70% of patients at discharge. The target market for CABG is estimated at USD\$2 billion worldwide and the target market for similar related diseases, such as stroke and TBI is estimated at USD\$4.5 billion worldwide.

About the Jackson Foundation

The Jackson Foundation is a private, not-for-profit organisation that supports the US military in conducting medical research and clinical trials and has established relationships with more than 160 military medical organisations worldwide. It was founded in 1983, in part, to foster cooperative relationships between the military medical community and the private sector, including pharmaceutical sponsors.

The Jackson Foundation manages Phase 1 - 4 clinical trials utilising an established network of military medical centres across the USA.



About Glypromate®

Glypromate® is a naturally occurring peptide fragment that is found in normal brain tissue. When injected intravenously, Glypromate® has been shown to act by multiple pathways in protecting brain tissue from injury. Glypromate® is a potential therapeutic candidate for diseases caused by some form of chronic or acute brain injury.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of neuroprotection and metabolic disorders. The Neuren portfolio consists of five product families, targeting markets with large unmet needs and limited competition. Neuren has two lead, clinical candidates, Glypromate® and NNZ-2566, presently in development to treat a range of acute neurological conditions. Neuren has commercial and development partnerships, including with Pfizer, the US Army's Walter Reed Army Institute of Research and Metabolic Pharmaceuticals.

For more information, please visit Neuren's website at www.neurenpharma.com

Contact details

Company	Media and investor relations
David Clarke CEO of Neuren T: 1800 259 181 (Australia) T: +64 9 3 367 7167 ext 82308(New Zealand) M: +64 21 988 052	Rebecca Piercy Buchan Consulting T: +61 3 9866 4722 M: +61 422 916 422